SOPHiA GENETICS SA (SOPH) Form 6-K — Aug 4, 2026
SOPHiA GENETICS reported second quarter 2026 revenue of $23.3 million, representing a 27% increase year-over-year, driven by a 22% rise in platform analysis volume and strong growth in the U.S. and Liquid Biopsy segments. The company raised its full-year 2026 revenue guidance to a range of $94 million to $96 million, up from the previous range of $92 million to $94 million, citing accelerating momentum in BioPharma and solid execution across its commercial operations.
Key figures
- Revenue
- 23310000
- Guidance
- Full year revenue between $94 million and $96 million; Adjusted EBITDA loss between $29 million and $32 million
- Total Debt
- 47999000
- Revenue Yoy
- 27%
- Cash Position
- 107665000
- Net Dollar Retention
- 117%
- Core Genomics Customers
- 542
- Platform Analysis Volume Q2
- 115432
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.